PDF(Pubmed)
Abstract：
We aimed to assess the therapeutic effects of a topical probiotic nano-formulation derived from Lactobacillus reuteri on treating recurrent aphthous stomatitis.
60 participants were randomly allocated into two groups (control and probiotic). Probiotic group administered topical probiotic nano-formulation three times a day for seven days. The control group administered a standard analgesic oral rinse. The size of ulcer(s) and pain severity were recorded on days 0, 3, 5, and 7 after intervention.
Before the intervention, the groups had no significant differences in terms of pain severity (P-value = 0.28) and lesion size (P-value = 0.24). Both groups exhibited significant reductions in pain severity and lesion size over the course of the intervention. After one week, the probiotic group had a notably larger lesion size reduction than the control group (P-value = 0.01). The probiotic group also showed a significantly greater reduction in pain severity than the control group (P-value = 0.04).
Applying topical probiotic nano-formulation derived from Lactobacillus reuteri three times a day decreased lesion size and pain severity in RAS patients faster than the local analgesic oral rinse.
Lactobacillus reuteri-derived probiotic nano-formulation might be a promising treatment option for RAS.
60 participants were randomly allocated into two groups (control and probiotic). Probiotic group administered topical probiotic nano-formulation three times a day for seven days. The control group administered a standard analgesic oral rinse. The size of ulcer(s) and pain severity were recorded on days 0, 3, 5, and 7 after intervention.
Before the intervention, the groups had no significant differences in terms of pain severity (P-value = 0.28) and lesion size (P-value = 0.24). Both groups exhibited significant reductions in pain severity and lesion size over the course of the intervention. After one week, the probiotic group had a notably larger lesion size reduction than the control group (P-value = 0.01). The probiotic group also showed a significantly greater reduction in pain severity than the control group (P-value = 0.04).
Applying topical probiotic nano-formulation derived from Lactobacillus reuteri three times a day decreased lesion size and pain severity in RAS patients faster than the local analgesic oral rinse.
Lactobacillus reuteri-derived probiotic nano-formulation might be a promising treatment option for RAS.
摘要：
目的：我们旨在评估源自罗伊氏乳杆菌的局部益生菌纳米制剂治疗复发性口疮性口炎的治疗效果。
方法：将60名参与者随机分为两组（对照组和益生菌组）。益生菌组每天三次施用局部益生菌纳米制剂,持续七天。对照组给予标准止痛剂口腔冲洗液。在干预后第0、3、5和7天记录溃疡的大小和疼痛严重程度。
结果：干预前，两组在疼痛严重程度(P值=0.28)和病变大小(P值=0.24)方面无显著差异.在干预过程中，两组的疼痛严重程度和病变大小均显着降低。一周后,益生菌组比对照组有明显更大的病灶缩小(P值=0.01).益生菌组还显示出疼痛严重程度比对照组显著更大的降低(P值=0.04)。
结论：在RAS患者中，每天三次局部应用罗伊乳杆菌衍生的益生菌纳米制剂比局部镇痛药口腔冲洗更快地降低病变大小和疼痛严重程度。
结论：罗伊氏乳杆菌衍生的益生菌纳米制剂可能是治疗RAS的一种有希望的选择。
方法：将60名参与者随机分为两组（对照组和益生菌组）。益生菌组每天三次施用局部益生菌纳米制剂,持续七天。对照组给予标准止痛剂口腔冲洗液。在干预后第0、3、5和7天记录溃疡的大小和疼痛严重程度。
结果：干预前，两组在疼痛严重程度(P值=0.28)和病变大小(P值=0.24)方面无显著差异.在干预过程中，两组的疼痛严重程度和病变大小均显着降低。一周后,益生菌组比对照组有明显更大的病灶缩小(P值=0.01).益生菌组还显示出疼痛严重程度比对照组显著更大的降低(P值=0.04)。
结论：在RAS患者中，每天三次局部应用罗伊乳杆菌衍生的益生菌纳米制剂比局部镇痛药口腔冲洗更快地降低病变大小和疼痛严重程度。
结论：罗伊氏乳杆菌衍生的益生菌纳米制剂可能是治疗RAS的一种有希望的选择。
